These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2761699)

  • 1. Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells.
    Pachner AR
    Neurology; 1989 Aug; 39(8):1057-61. PubMed ID: 2761699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis.
    Vernet-der Garabedian B; Morel E; Bach JF
    J Neuroimmunol; 1986 Jul; 12(1):65-74. PubMed ID: 3711314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
    Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
    Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen.
    Somnier FE
    J Neuroimmunol; 1994 Apr; 51(1):63-8. PubMed ID: 8157737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ligand antibodies as potential autoantigens: in vitro and in vivo characteristics of anti-bungarotoxin antibodies in the idiotype network.
    Pachner AR; Itano AA; McCallum RM; Ricalton NS
    Autoimmunity; 1991; 10(2):145-52. PubMed ID: 1782327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
    Vernet-der-Garabédian B; Morel E; Bach JF
    C R Acad Sci III; 1984; 298(16):449-56. PubMed ID: 6428718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
    Vernet-der Garabedian B; Bach JF; Morel E
    Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyosarcoma cell line can be used for the isolation of soluble acetylcholine receptor and for assaying blocking and modulating autoantibodies.
    Wu JT; Astill M; Lloyd C; Salmon VC
    J Clin Lab Anal; 1993; 7(1):11-8. PubMed ID: 8426270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future therapeutic strategies in autoimmune myasthenia gravis.
    Psaridi-Linardaki L; Mamalaki A; Tzartos SJ
    Ann N Y Acad Sci; 2003 Sep; 998():539-48. PubMed ID: 14592926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and pharmacological heterogeneity of alpha-bungarotoxin binding sites extracted from TE671 cells.
    Walker R; Vincent A; Newsom-Davis J
    J Neuroimmunol; 1988 Aug; 19(1-2):149-57. PubMed ID: 3397405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and functional properties of the acetylcholine receptor expressed on the human cell line TE671.
    Stuhlmüller B; Kalden JR; Fahlbusch R; Hain N; Manger B
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):657-65. PubMed ID: 8292667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of radioimmunoassay procedures for determination of anti-acetylcholine receptor antibodies in the sera of patients with myasthenia gravis.
    Carter B; Harrison R; Lunt GG; Morris H; Savage-Marengo T; Stephenson FA
    Ann Clin Biochem; 1981 May; 18(Pt 3):146-52. PubMed ID: 7283364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravis.
    Trotter JL; Ringel SP; Cook JD; Engel WK; Eldefrawi ME; McFarlin DE
    Neurology; 1977 Dec; 27(12):1120-4. PubMed ID: 73154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.
    Tzartos SJ; Sophianos D; Zimmerman K; Starzinski-Powitz A
    J Immunol; 1986 May; 136(9):3231-8. PubMed ID: 3958494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671.
    Voltz R; Hohlfeld R; Fateh-Moghadam A; Witt TN; Wick M; Reimers C; Siegele B; Wekerle H
    Neurology; 1991 Nov; 41(11):1836-8. PubMed ID: 1944918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
    Barkas T; Simpson JA
    J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in 'antibody-negative' myasthenia gravis.
    Brooks EB; Pachner AR; Drachman DB; Kantor FS
    J Neuroimmunol; 1990 Jun; 28(1):83-93. PubMed ID: 2341562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor.
    Blaes F; Beeson D; Plested P; Lang B; Vincent A
    Ann Neurol; 2000 Apr; 47(4):504-10. PubMed ID: 10762162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of acetylcholine receptors: different forms of receptor distinguished by alpha-bungarotoxin kinetics and by antibody binding properties.
    Massa T; Mittag TW
    J Pharmacol Exp Ther; 1983 Nov; 227(2):340-8. PubMed ID: 6631716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.